OBJECTIVES: The goal of this study was to evaluate the prospective association of fetuin-A levels with cardiovascular disease (CVD) mortality. BACKGROUND: Fetuin-A is a circulating inhibitor of calcium deposition in the vasculature and of insulin action in muscle and fat, and may be involved in the pathogenesis of CVD. METHODS: This is a population-based prospective study of 633 men and 1,025 women (median age = 73 years) who had fetuin-A levels and CVD risk factors evaluated in 1992 to 1996 and were followed for vital status through 2010. RESULTS: Plasma fetuin-A (g/l ± SD) was highest in women using oral estrogens (0.55 ± 0.12), intermediate for women not using oral estrogens (0.51 ± 0.10), and lowest for men (0.50 ± 0.10), p < 0.001. Lower fetuin-A levels were associated with older age, but with lower levels of other CVD risk factors including adiposity, blood pressure, lipids, triglycerides, and insulin resistance (all p < 0.01). During the median 12-year follow-up, 273 deaths were attributed to CVD. The association of fetuin-A with CVD mortality differed by diabetes status (p for interaction = 0.003). Adjusting for age, sex, oral estrogens, and lifestyle, the hazard ratio for CVD mortality comparing the lowest fetuin-A quartile with all higher values was 1.76 (95% confidence interval [CI]: 1.34 to 2.31; p < 0.001) for participants without diabetes and 0.43 (95% CI: 0.19 to 0.98; p = 0.046) for participants with diabetes. CONCLUSIONS: Low fetuin-A levels predicted greater risk for CVD mortality in older adults without diabetes, but were associated with reduced risk of CVD death in those with diabetes. Fetuin-A may provide novel insight into mechanisms leading to CVD death in those with versus without diabetes.
OBJECTIVES: The goal of this study was to evaluate the prospective association of fetuin-A levels with cardiovascular disease (CVD) mortality. BACKGROUND:Fetuin-A is a circulating inhibitor of calcium deposition in the vasculature and of insulin action in muscle and fat, and may be involved in the pathogenesis of CVD. METHODS: This is a population-based prospective study of 633 men and 1,025 women (median age = 73 years) who had fetuin-A levels and CVD risk factors evaluated in 1992 to 1996 and were followed for vital status through 2010. RESULTS: Plasma fetuin-A (g/l ± SD) was highest in women using oral estrogens (0.55 ± 0.12), intermediate for women not using oral estrogens (0.51 ± 0.10), and lowest for men (0.50 ± 0.10), p < 0.001. Lower fetuin-A levels were associated with older age, but with lower levels of other CVD risk factors including adiposity, blood pressure, lipids, triglycerides, and insulin resistance (all p < 0.01). During the median 12-year follow-up, 273 deaths were attributed to CVD. The association of fetuin-A with CVD mortality differed by diabetes status (p for interaction = 0.003). Adjusting for age, sex, oral estrogens, and lifestyle, the hazard ratio for CVD mortality comparing the lowest fetuin-A quartile with all higher values was 1.76 (95% confidence interval [CI]: 1.34 to 2.31; p < 0.001) for participants without diabetes and 0.43 (95% CI: 0.19 to 0.98; p = 0.046) for participants with diabetes. CONCLUSIONS: Low fetuin-A levels predicted greater risk for CVD mortality in older adults without diabetes, but were associated with reduced risk of CVD death in those with diabetes. Fetuin-A may provide novel insight into mechanisms leading to CVD death in those with versus without diabetes.
Authors: Joachim H Ix; Glenn M Chertow; Michael G Shlipak; Vincent M Brandenburg; Markus Ketteler; Mary A Whooley Journal: Nephrol Dial Transplant Date: 2006-04-27 Impact factor: 5.992
Authors: Norbert Stefan; Anita M Hennige; Harald Staiger; Jürgen Machann; Fritz Schick; Stefan M Kröber; Fausto Machicao; Andreas Fritsche; Hans-Ulrich Häring Journal: Diabetes Care Date: 2006-04 Impact factor: 19.112
Authors: Joachim H Ix; Michael G Shlipak; Vincent M Brandenburg; Sadia Ali; Markus Ketteler; Mary A Whooley Journal: Circulation Date: 2006-03-27 Impact factor: 29.690
Authors: Peter Stenvinkel; Kai Wang; Abdul Rashid Qureshi; Jonas Axelsson; Roberto Pecoits-Filho; Ping Gao; Peter Barany; Bengt Lindholm; Tomas Jogestrand; Olof Heimbürger; Clifford Holmes; Martin Schalling; Louise Nordfors Journal: Kidney Int Date: 2005-06 Impact factor: 10.612
Authors: Joachim H Ix; Glenn M Chertow; Michael G Shlipak; Vincent M Brandenburg; Markus Ketteler; Mary A Whooley Journal: Circulation Date: 2007-05-07 Impact factor: 29.690
Authors: Jens J Kaden; Jochen O Reinöhl; Birgit Blesch; Martina Brueckmann; Dariusch Haghi; Martin Borggrefe; Fabian Schmitz; Sebastian Klomfass; Manuela Pillich; Jan R Ortlepp Journal: Int J Mol Med Date: 2007-08 Impact factor: 4.101
Authors: Monik C Jiménez; Qi Sun; Markus Schürks; Frank B Hu; Joann E Manson; Kathryn M Rexrode Journal: Clin Chem Date: 2013-10-29 Impact factor: 8.327
Authors: Julia J Scialla; W H Linda Kao; Ciprian Crainiceanu; Stephen M Sozio; Pooja C Oberai; Tariq Shafi; Josef Coresh; Neil R Powe; Laura C Plantinga; Bernard G Jaar; Rulan S Parekh Journal: Clin J Am Soc Nephrol Date: 2014-01-23 Impact factor: 8.237
Authors: Gail A Laughlin; Linda K McEvoy; Elizabeth Barrett-Connor; Lori B Daniels; Joachim H Ix Journal: Clin Endocrinol (Oxf) Date: 2014-01-07 Impact factor: 3.478
Authors: Sarah A Aroner; David E St-Jules; Kenneth J Mukamal; Ronit Katz; Michael G Shlipak; Michael H Criqui; Bryan Kestenbaum; David S Siscovick; Ian H de Boer; Nancy S Jenny; Matthew J Budoff; Joachim H Ix; Majken K Jensen Journal: Atherosclerosis Date: 2016-03-22 Impact factor: 5.162